Hims & Hers Health (NYSE: HIMS) delivered a third quarter that looks like two different stories depending on which metric you lead with. Revenue surged 49% year-over-year to $890.4 million, a second consecutive quarter of acceleration, and international revenue exploded 321% to $233.3 million. GAAP net income flipped to a $33.0 million loss from a $15.8 million profit a year ago. Full-year Adjusted EBITDA guidance was lowered to $257 million to $277 million from a prior range that implied a higher midpoint. The divergence is intentional, not accidental.
The headline miss on EPS ($0.14 loss vs. $0.06 estimate) and the GAAP loss are largely explained by one line item: stock-based compensation hit $64.5 million in the quarter, up 60% from a year ago. Add $35.4 million in acquisition, transaction, and investment earn-out costs plus $3.8 million in restructuring charges, and the adjusted picture looks different. Adjusted EBITDA actually rose slightly to $82.4 million from $78.4 million; adjusted net income came in at $6.5 million. The GAAP loss is real but not operational in the way most investors would interpret it.

Gross margin tells a more structural story. It compressed to 57% from 74% a year ago, a 1700bp decline driven by product mix and platform investments. The company is selling more lower-margin products, particularly internationally, and investing in fulfillment and technology. The adjusted gross margin, which strips out restructuring charges in cost of revenue, sits at the same 57% for the quarter. This is not a one-time blip. The margin compression reflects a deliberate shift toward scale over near-term profitability, and the full-year guide implies that compression will persist.
The guidance change is the real signal. Full-year revenue guidance was tightened to $3.13 billion to $3.15 billion, essentially in line with the prior range. But Adjusted EBITDA guidance was lowered to $257 million to $277 million, implying an 8% to 9% margin at the midpoint. That is down from the 15% adjusted EBITDA margin the company reported for the first nine months of 2025. Management explicitly cited intentional pacing of marketing spend ahead of planned fourth-quarter platform expansions. CFO Yemi Okupe said the company is "intentionally pacing marketing spend ahead of several planned expansions to our platform in the fourth quarter." The message is clear: the company is trading near-term margin for long-term positioning.
Subscriber growth was solid but not spectacular. Subscribers reached 2.8 million, up 13% year-over-year. The more interesting number is monthly revenue per average subscriber, which jumped 30% to $105. That suggests the company is successfully upselling existing customers into higher-value treatments and services, a dynamic that supports the investment thesis even as margins compress. The international business, now 26% of total revenue, is growing from a small base but at a pace that justifies the infrastructure spend.
The balance sheet remains a source of flexibility. Cash and equivalents stood at $605.6 million at quarter end, up from $228.6 million at year-end 2025, driven by a $390.4 million convertible note issuance. Free cash flow was $26.0 million in the quarter, down from $79.4 million a year ago, reflecting higher capex and working capital needs tied to growth. The company has room to invest.
The forward read is about execution on the fourth-quarter expansions. Management is signaling that the investments made in Q3 will bear fruit in Q4 and into 2027. The lowered EBITDA guide for the full year implies Q4 adjusted EBITDA of $70 million to $90 million, which at the midpoint would be roughly flat with Q3. That is not a margin recovery quarter. Investors should watch whether subscriber growth accelerates in Q4 and whether the revenue per subscriber trend holds. If it does, the margin story becomes a bridge to a higher-margin future. If it does not, the compression looks more like a permanent shift in the business model.
